AlphAIAlphAI — Financial news for AI agents
investing.comOCT 302 min read$SYK

Piper Sandler cuts Stryker stock price target on Q3 miss

Piper Sandler reduced its price target for Stryker (NYSE:SYK) to $325 from $390 after Q3 results missed expectations. The company lowered its full-year guidance, citing deceleration in the large joint market. Shares are down 24% from their 52-week high. Multiple analysts have adjusted their targets and ratings following the earnings report.

Original reporting
investing.com
Published Oct 30, 2026, 4:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 4:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$SYK
Bearish
high confidence
Mentioned
$SYK
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SYKBearishHigh
01

Why it matters

The earnings miss and guidance reduction triggered a series of price‑target cuts, indicating heightened downside risk.

02

Market read

Stryker's earnings shortfall and subsequent analyst downgrades create a bearish short‑term outlook for the stock.

03

What to watch

Potential upside from upcoming product launches and a relatively low valuation after the price target cut.

Relevance 8/10Novelty 8/10Timing: after-hours reaction

Background

Stryker reported Q3 2026 revenue of $6.52 B and EPS of $3.52, both below consensus, prompting multiple analysts to trim targets.

Company-level read

Ticker impact

$SYKBearishHigh confidence
Context

Piper Sandler lowered Stryker's price target to $325 after the company's Q3 2026 earnings miss and guidance cut.

Expected impact

likely pressure as the market prices in weaker earnings and lower guidance

Evidence & confidence

Analyst target reduction and earnings miss typically drive short-term sell pressure.

Market effects

Sector

Medical technology sector may see broader scrutiny as Stryker's slowdown hints at demand pressure in orthopedics.

Regional

U.S. healthcare stocks could face modest pullback in the near term.

Global

Limited to investors with exposure to U.S. med‑tech equities.

Counterpoint

What could challenge this read

If the market overreacts, Stryker's new products and 6‑7% revenue growth outlook could support a rebound.

Key entities

  • Analyst
    Piper Sandler

    Research firm that lowered the price target to $325.

  • Analyst
    RBC Capital

    Reduced target to $375 after guidance cut.

Read at source← All news

StoryStryker cuts FY 2026 outlook after Q3 miss and operational setbacks

Also covered by

4 outlets

Related articles

OCT 30
$SYKMedAI 8/10

Stryker (SYK) Q3 2026 Earnings Call Transcript

Stryker (SYK) reported Q3 2026 earnings, with organic sales growth of 7.7% and adjusted EPS of $3.52. The company faced delays in new product sales due to a cyber incident and SAP implementation but remains confident in long-term growth. Stryker updated its guidance, expecting similar Q4 growth. Recent acquisitions include ZuriMED and an investment in CMR Surgical. Vascular business showed sequential improvement, and the company anticipates commercializing AVS' IVL platform in 2027.

finance.yahoo.com8 min
OCT 30
$SYKHighAI 9/10

Stryker lowers 2026 guidance after slowdown in hip, knee procedures

Stryker reported Q3 revenue of $6.5B, up 7.7% YoY, but net earnings fell 12.3% YoY. CEO Kevin Lobo cited a market slowdown in hip and knee procedures due to economic challenges. The company lowered its 2026 sales guidance to 6.5-7.0% from 8.3-9.3%. Lobo will step down as CEO at year-end, succeeded by COO Spencer Stiles. Stryker also invested $400M in CMR Surgical for U.S. distribution rights.

finance.yahoo.com2 min
OCT 30
$SYKMed

Stryker stock downgraded by Canaccord on weak execution, market slowdown

Canaccord downgraded Stryker (SYK) to Hold with a $300 price target, citing weak Q3 results and a slowdown in the knee and hip replacement market. 14 analysts revised earnings downward. Stryker reported Q3 revenue of $6.52B, missing estimates, and lowered its full-year guidance. Despite challenges, the company maintains a strong financial position with a perfect Piotroski Score and 16 consecutive years of dividend increases.

investing.com3 min